2011
DOI: 10.1016/s2173-5808(11)70006-2
|View full text |Cite
|
Sign up to set email alerts
|

Analysis of direct, indirect, and intangible costs of epilepsy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 33 publications
0
2
0
Order By: Relevance
“…This evidence has different potential explanations. Cultural interpretation can contribute to the perception of seizures as stigma and to the attribution of an overestimated severity. Patients from developing countries may be more likely to have experienced healthcare systems characterized by longer delays before accessing modern treatments, reduced AED choice and accessibility, and limited human and technical resources for epilepsy.…”
Section: Discussionmentioning
confidence: 99%
“…This evidence has different potential explanations. Cultural interpretation can contribute to the perception of seizures as stigma and to the attribution of an overestimated severity. Patients from developing countries may be more likely to have experienced healthcare systems characterized by longer delays before accessing modern treatments, reduced AED choice and accessibility, and limited human and technical resources for epilepsy.…”
Section: Discussionmentioning
confidence: 99%
“…While epilepsy is the fourth most common neurological condition, studies investigating the characteristics and burden of medically refractory epilepsy patients who suffer from frequent seizures are scarce, with most studies focusing on the pediatric population. Although previous studies have measured the HRQoL of adults with medically refractory epilepsy or the socioeconomic impact of this disease, only a few studies have assessed these issues jointly ( 11 14 ). Moreover, these studies often measured HRQoL using disease-specific rather than generic instruments, hampering the comparability of outcomes with other patient populations and their use in economic evaluations.…”
Section: Introductionmentioning
confidence: 99%